Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.40 |
| ▸ | KDR | P35968 | 9/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14560330 | 0.89 | GPR17 (0.41) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL23514555 | 0.86 | HPGD (0.40) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL14560308 | 0.86 | HPGD (0.39) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL5540868 | 0.81 | PIM1 (0.32) | — | |
| SCHEMBL14560306 | 0.81 | HPGD (0.37) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL4405135 | 0.81 | PDGFRB (0.53) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL7821237 | 0.78 | PDGFRB (0.53) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL14560370 | 0.76 | CYP4F2 (0.42) | PDGFRBNPSR1CYP2C19SRC | |
| SCHEMBL6809231 | 0.73 | PDGFRB (0.46) | PDGFRBFGFR1KDRZAP70NPSR1 | |
| SCHEMBL5830668 | 0.72 | NPSR1 (0.43) | NPSR1GPR17HPGDCYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6395734-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1082305-A4 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1082305-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | DMPK, PDPK1, PLK2 | PDGFRB 1086/4885FGFR1 930/4885KDR 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.